Market Overview

HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets

HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets

G1 Therapeutics Inc (NASDAQ: GTHX), a clinical-stage biopharmaceutical company that focuses on novel oncology therapeutics, boasts three drug candidates that address "potential blockbuster" markets, according to H.C. Wainwright.

The Analyst

H.C. Wainwright's Edward White initiated coverage of G1 Therapeutics' stock with a Buy rating and $61 price target.

The Thesis

G1 Therapeutics is positioning itself to help the approximate 1 million patients annually in the U.S. who undergo chemotherapy with its therapies, White said in a Tuesday initiation note.

Trilaciclib is intended to improve patient outcomes by maximizing the effects of a chemotherapy treatment while simultaneously minimizing myelosuppression and immunosuppression, White said. Investors could be overlooking the possibility of trilaciclib becoming part of the standard of care for patients with CDK4/6-independent tumors, including small cell lung cancer and triple-negative breast cancer, he said. 

G1's second drug in development, G1T38, could become a best-in-class treatment versus existing treatments such as ibrance, kisqali and verzenio, the analyst said. The company's third drug, G1T48, is an oral selective estrogen receptor degrader that could perform well against existing therapies like faslodex, he said. 

G1 could even combine G1T48 with G1T38 to create a wholly owned, all-oral SERD and CDK4/6 inhibitor combination regime that would hold a commercialization advantage, White said. That outcome would have a size and scale investors are "not fully understanding," he said. 

Price Action

G1 Therapeutics shares were trading lower by 3.6 percent Tuesday afternoon at $48.26. 

Related Links:

Exclusive: Ziopharm Oncology CEO Wants To Disrupt The CAR-T Supply Chain

NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade

Latest Ratings for GTHX

Aug 2020WedbushMaintainsOutperform
May 2020JP MorganMaintainsOverweight
Feb 2020WedbushMaintainsOutperform

View More Analyst Ratings for GTHX
View the Latest Analyst Ratings


Related Articles (GTHX)

View Comments and Join the Discussion!

Posted-In: cancer Cancer TherapiesAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

WKHSRoth CapitalMaintains15.0
HCKTRoth CapitalMaintains22.0
ARECRoth CapitalInitiates Coverage On7.5
SLABWells FargoMaintains180.0
PENWells FargoMaintains310.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at